Song Minkyo, Jayasekara Harindra, Pelucchi Claudio, Rabkin Charles S, Johnson Kenneth C, Hu Jinfu, Palli Domenico, Ferraroni Monica, Liao Linda M, Bonzi Rossella, Zaridze David, Maximovitch Dmitry, Aragonés Nuria, Martin Vicente, Castaño-Vinyals Gemma, Guevara Marcela, Tsugane Shoichiro, Hamada Gerson Shigueaki, Hidaka Akihisa, Negri Eva, Ward Mary H, Sinha Rashmi, Lagiou Areti, Lagiou Pagona, Boffetta Paolo, Curado Maria Paula, Lunet Nuno, Vioque Jesus, Zhang Zuo-Feng, La Vecchia Carlo, Camargo M Constanza
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.
Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, VIC, Australia.
Cancer Causes Control. 2024 Apr;35(4):727-737. doi: 10.1007/s10552-023-01829-1. Epub 2023 Dec 20.
Gastric cancer incidence is higher in men, and a protective hormone-related effect in women is postulated. We aimed to investigate and quantify the relationship in the Stomach cancer Pooling (StoP) Project consortium.
A total of 2,084 cases and 7,102 controls from 11 studies in seven countries were included. Summary odds ratios (ORs) and 95% confidence intervals (CIs) assessing associations of key reproductive factors and menopausal hormone therapy (MHT) with gastric cancer were estimated by pooling study-specific ORs using random-effects meta-analysis.
A duration of fertility of ≥ 40 years (vs. < 20), was associated with a 25% lower risk of gastric cancer (OR = 0.75; 95% CI: 0.58-0.96). Compared with never use, ever, 5-9 years and ≥ 10 years use of MHT in postmenopausal women, showed ORs of 0.73 (95% CI: 0.58-0.92), 0.53 (95% CI: 0.34-0.84) and 0.71 (95% CI: 0.50-1.00), respectively. The associations were generally similar for anatomical and histologic subtypes.
Our results support the hypothesis that reproductive factors and MHT use may lower the risk of gastric cancer in women, regardless of anatomical or histologic subtypes. Given the variation in hormones over the lifespan, studies should address their effects in premenopausal and postmenopausal women. Furthermore, mechanistic studies may inform potential biological processes.
胃癌发病率男性高于女性,推测女性存在激素相关的保护作用。我们旨在胃癌合并研究(StoP)项目联盟中调查并量化这种关系。
纳入了来自7个国家11项研究的2084例病例和7102例对照。通过随机效应荟萃分析合并各研究的比值比(OR),估计关键生殖因素和绝经激素治疗(MHT)与胃癌关联的汇总OR及95%置信区间(CI)。
生育期≥40年(对比<20年),与胃癌风险降低25%相关(OR = 0.75;95% CI:0.58 - 0.96)。与从未使用MHT相比,绝经后女性曾经使用、使用5 - 9年及≥10年的OR分别为0.73(95% CI:0.58 - 0.92)、0.53(95% CI:0.34 - 0.84)和0.71(95% CI:0.50 - 1.00)。解剖学和组织学亚型的关联总体相似。
我们的结果支持以下假设,即生殖因素和MHT的使用可能降低女性患胃癌的风险,无论解剖学或组织学亚型如何。鉴于一生中激素的变化,研究应探讨其在绝经前和绝经后女性中的作用。此外,机制研究可能有助于了解潜在的生物学过程。